Robert Flanagan - Sagent Pharmaceuticals Lead Independent Director
Director
Mr. Robert Flanagan is a Chairman of the Board Lead Independent Director of Sagent Pharmaceuticals Inc. Mr. Flanagan has served as a member of our Board since May 2009 including as our lead director from April 2012 to June 2015 and as our chairman since June 2015. Mr. Flanagan has held the position of President of Clark Enterprises Inc. since 2015 and was its Executive Vice President from 1989 to 2015. At Clark Enterprises Mr. Flanagan oversees the acquisition management and development of new investment opportunities. Prior to that Mr. Flanagan served as the treasurer secretary and a member of the board of directors of Baltimore Orioles Inc. Mr. Flanagan has also served on the board of directors of Martek Biosciences Corporation where he served as Chairman and Castle Brands Inc. and is a Certified Public Accountant licensed in Washington D.C. As a result of these and other professional experiences we believe Mr. Flanagan possesses knowledge and experience in accounting finance and capital structure strategic planning and leadership of complex organizations people management board governance and board practices of other entities that strengthen the Boards collective qualifications skills and experience since 2015.
| Age | 59 |
| Tenure | 9 years |
| Phone | 847 908-1600 |
| Web | www.sagentpharma.com |
Sagent Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (5.8118) % which means that it has lost $5.8118 on every $100 spent on assets. This is way below average. Sagent Pharmaceuticals' management efficiency ratios could be used to measure how well Sagent Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 1.62 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Sagent Pharmaceuticals has a current ratio of 2.12, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Sagent Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Sagent Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sagent Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sagent to invest in growth at high rates of return. When we think about Sagent Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Craig Ramsey | National CineMedia | 63 | |
| Arthur Schaier | Hanover Foods | 66 | |
| Michael Beindorff | Lifevantage | 63 | |
| Raymond Greer | Lifevantage | 53 | |
| Allan Bridgford | Bridgford Foods | 59 | |
| Mark Segall | National CineMedia | 55 | |
| David Toole | Lifevantage | 60 | |
| Cyril Noel | Hanover Foods | 83 | |
| David Haas | National CineMedia | 76 | |
| Edward Lippy | Hanover Foods | 78 | |
| George Metzger | Lifevantage | 69 | |
| Peter Brandow | National CineMedia | 55 | |
| Keith Ross | Bridgford Foods | 55 | |
| Richard Okumoto | Lifevantage | 63 | |
| Todd Andrews | Bridgford Foods | 52 | |
| Garry Mauro | Lifevantage | 67 | |
| Andrew Glaze | National CineMedia | 39 | |
| Renana Teperberg | National CineMedia | 40 | |
| Paula Madison | National CineMedia | 63 | |
| Bruce Bridgford | Bridgford Foods | 65 | |
| Stephen Lanning | National CineMedia | 62 | |
Management Performance
| Return On Equity | -8.0E-4 | |||
| Return On Asset | -5.81 |
Sagent Pharmaceuticals Leadership Team
Elected by the shareholders, the Sagent Pharmaceuticals' board of directors comprises two types of representatives: Sagent Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sagent. The board's role is to monitor Sagent Pharmaceuticals' management team and ensure that shareholders' interests are well served. Sagent Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sagent Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ronald Pauli, CFO | ||
| ChenMing Yu, Independent Director | ||
| Shlomo Yanai, Director | ||
| Anthony Krizman, Independent Director | ||
| Jeffrey Greve, Principal Accounting Officer, VP and Controller | ||
| Dave Hebeda, Vice President - Finance | ||
| Jonathon Singer, CFO and Executive VP | ||
| Ravi Malhotra, Vice President - Project Management | ||
| Sean Brynjelsen, Executive Vice President Business Development | ||
| Lorin Drake, Executive VP of Sales | ||
| Anthony Gulczynski, Vice President - Corporate Development | ||
| Michael Logerfo, President, Chief Legal Officer and Corporate Secretary | ||
| Jeffrey Yordon, Founder and Director | ||
| Mary Behrens, Independent Director | ||
| James Sperans, Independent Director | ||
| Frank Harmon, Executive Vice President - Global Operations | ||
| Allan Oberman, CEO and Director | ||
| Robert Flanagan, Lead Independent Director | ||
| Albert Patterson, Executive Vice President - National Accounts and Corporate Development | ||
| Frank Kung, Independent Director | ||
| Michael Ward, Corporate Secretary, Chief Legal Officer | ||
| Tom Moutvic, Vice President - Regulatory Affairs | ||
| Michael Fekete, Independent Director | ||
| Sheila Moran, Vice President - Quality |
Sagent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sagent Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.0E-4 | |||
| Return On Asset | -5.81 | |||
| Profit Margin | (6.68) % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 497.53 M | |||
| Shares Outstanding | 32.44 M | |||
| Shares Owned By Insiders | 27.74 % | |||
| Shares Owned By Institutions | 76.80 % | |||
| Number Of Shares Shorted | 1.57 M | |||
| Price To Earning | 29.79 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Sagent Stock
If you are still planning to invest in Sagent Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sagent Pharmaceuticals' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |